摘要
目的:探讨胰腺癌组织E-cadherin(E-cad,上皮钙粘附素)5’-CpG岛异常甲基化情况;进一步讨论DNA异常甲基化在临床早期诊断、预后中的应用。方法:应用甲基化特异性PCR(MSP)检测27例胰腺癌组织和9例良性胰腺组织E-cad基因甲基化情况。结果:①在9例胰腺良性肿瘤及正常胰腺组织中,E-cad基因非甲基化PCR扩增均为阳性,未见甲基化PCR扩增。②在27例胰腺癌组织E-cad基因甲基化PCR扩增阳性9例(33.33%,9/27),其中完全甲基化6例,部分甲基化3例;而非甲基化PCR扩增阳性为18例(66.67%,18/27)。③E-cad基因异常甲基化与性别、年龄大小、肿瘤大小之间均无显著性差异(P>0.05),但与肿瘤的组织学分级相关。结论:在胰腺癌组织中E-cad基因异常甲基化是胰腺癌组织区别于其它胰腺良性病变的生物学标志之一。
Objective:To study the aberrant methylation status of E-cadherin genes in pancreatic carcinoma.Methods:Adoption of methylation-specific PCR(MSP)the CpG island methylation of E-cadherin genes in surgically resected pancreatic carcinoma(PC) tissues and benign pancreatic tissues was assessed.Results:1)No aberrant methylation of E-cad gene in 9 cases with normal and benign pancreatic tissues was assessed.2)Among 27 cases with pancreatic carcinoma, aberrant methylation positive rate of E-cad was 33.33%(9/27).3)No significant relationship was found between methylation of E-cad and clinicopathological characteristics including age,sex,and tumor size,but the methylation of E-cad was found to be associated with tumor histological differentiation.Conclusion:Our result showed that E-cad gene methylation was an important biomarker of carcinoma.
出处
《华西医学》
CAS
2005年第2期216-217,共2页
West China Medical Journal
